Acc inhibitors and uses thereof

Abstract

The present invention provides compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.

1 . A compound of formula I or II: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof, wherein: 
         X is selected from —O—, —S—, or —N(R)—; 
         each of Q 1  and Q 2  is independently O or S; 
         R 1  is hydrogen, halogen, —CN, —NO 2 , —R 6 , —OR, or —SR; 
         R 2  is hydrogen, halogen, —R 6 , —OR, —SR, —N(R) 2 , —N(R)C(O)R, —C(O)N(R) 2 , —N(R)C(O)N(R) 2 , —N(R)C(O)OR, —OC(O)N(R) 2 , —N(R)S(O) 2 R, —S(O) 2 N(R) 2 , —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, —S(O) 2 R, or Hy; or
 R 1  and R 2  may optionally be taken together to form an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic carbocyclo-, or heterocyclo-, benzo-, or a 5-6 membered heteroarylo-fused ring; 
 
         Hy is an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 
         each R is independently selected from hydrogen, deuterium, and an optionally substituted group selected from C 1-6  aliphatic; a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; an 8-10 membered bicyclic aryl ring; a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 
         L 1  is a covalent bond, an optionally substituted straight or branched bivalent C 1-6  hydrocarbon chain, or a cyclopropylenyl, cyclobutylenyl, or oxetanyl group; 
         R 3  is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from N, O, S, S(O), and S(O) 2 ; wherein R 3  is substituted with m instances of R 5 ; 
         L 2  is a covalent bond or a straight or branched bivalent C 1-6  hydrocarbon chain, wherein L 2  is substituted with p instances of —R 7 ; 
         R 4  is hydrogen or an optionally substituted ring selected from a 3-10 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; a 6-10 membered bicyclic saturated, partially unsaturated, or aryl ring; a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each R 4  may additionally be optionally substituted with n instances of —R 8 ; 
         each instance of R 5  is independently oxo, —R 6 , —OR, —SR, —N(R) 2 , —N(R)C(O)R, —C(O)N(R) 2 , —N(R)C(O)N(R) 2 , —N(R)C(O)OR, —OC(O)N(R) 2 , —N(R)SO 2 R, —SO 2 N(R) 2 , —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, and —S(O) 2 R; or
 two instances of R 5 , together with the atom(s) to which they are attached, form an optionally substituted 3-10 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 
 
         each R 6  is independently selected from deuterium, and an optionally substituted group selected from C 1-6  aliphatic; a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; an 8-10 membered bicyclic aryl ring; a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 
         each instance of R 7  is independently selected from oxo, —R 6 , —OR, —SR, —N(R) 2 , —N(R)C(O)R, —C(O)N(R) 2 , —N(R)C(O)N(R) 2 , —N(R)C(O)OR, —OC(O)N(R) 2 , —N(R)SO 2 R, —SO 2 N(R) 2 , —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, and —S(O) 2 R; 
         each R 8  is independently halogen, —R 6 , —OR, —SR, —N(R) 2  or deuterium; 
         each of m, n, and p is independently 0-5; and 
         Y is selected from —O—, —S—, or —N(R)—. 
       
     
     
         2 . The compound of  claim 1 , wherein R 3  is: 
       
         
           
           
               
               
           
         
       
     
     
         3 . The compound of  claim 2 , wherein R 3 (R 5 ) m , taken together, is: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         4 . The compound of  claim 3 , wherein R 3 (R 5 ) m , taken together, is: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         5 . The compound of  claim 1 , wherein R 1  is methyl. 
     
     
         6 . The compound of  claim 1 , wherein R 2  is Hy. 
     
     
         7 . The compound of  claim 6 , wherein Hy is: 
       
         
           
           
               
               
           
         
       
     
     
         8 . The compound of  claim 1 , wherein L 1  is a covalent bond. 
     
     
         9 . The compound of  claim 1 , wherein L 2  is ethylene, substituted with 1-2 instances of R 7 . 
     
     
         10 . The compound of  claim 9 , wherein L 2 (R 7 ) p  taken together, is: 
       
         
           
           
               
               
           
         
         wherein # represents the point of attachment to R 4 . 
       
     
     
         11 . The compound of  claim 10 , wherein L 2 (R 7 ) p  taken together, is: 
       
         
           
           
               
               
           
         
         wherein # represents the point of attachment to R 4 . 
       
     
     
         12 . The compound of  claim 1 , wherein R 4 (R 8 ) n , taken together is: 
       
         
           
           
               
               
           
         
       
     
     
         13 . The compound of  claim 1 , wherein the compound is selected from those depicted in Table 1 of the specification. 
     
     
         14 . A composition comprising a compound of  claim 1  and a pharmaceutically acceptable carrier, adjuvant, or vehicle. 
     
     
         15 . A method of inhibiting ACC in a patient in need thereof, comprising administering to said patient the compound of  claim 1 . 
     
     
         16 . A method of inhibiting ACC in a biological sample, comprising contacting the biological sample with the compound of  claim 1 . 
     
     
         17 .- 24 . (canceled) 
     
     
         25 . A composition for agriculture use comprising a compound of  claim 1 , or an agriculturally acceptable salt thereof, and an agriculturally acceptable carrier, optionally comprising an adjuvant, optionally comprising one or more additional pesticides, and optionally comprising one or more biological control agents, microbial extracts, natural products, plant growth activators or plant defense agents, or mixtures thereof. 
     
     
         26 . A method of controlling agricultural fungal pathogens, the method comprising administering the composition of  claim 25  to a plant, a seed or soil. 
     
     
         27 . A method of inhibiting ACC in a plant, comprising contacting the plant with the compound of  claim 1 .